Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program
Pediatric Blood & Cancer2007Vol. 50(1), pp. 37–45
Citations Over TimeTop 10% of 2007 papers
Peter J. Houghton, Christopher L. Morton, E. Anders Kolb, Richard B. Lock, Hernán Carol, C. Patrick Reynolds, Nino Keshelava, John M. Maris, Stephen T. Keir, Jianrong Wu, Malcolm A. Smith
Abstract
Administered at its MTD in mice, bortezomib demonstrated activity against selected lines of the PPTP's ALL in vivo panel. Further studies are indicated to determine the activity of bortezomib when combined with standard agents to treat childhood ALL.
Related Papers
- → Proteasome Inhibitors in Treatment of Multiple Myeloma(2013)3 cited
- Effect of Bortezomib on serum cystatin-C in multiple myeloma(2011)
- → Bortezomib:a proteasome inhibitor in the treatment of multiple myeloma(2008)
- → Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma(2016)
- → Mechanisms of proteasome inhibitor bortezomib on the therapy of multiple myeloma(2011)